RXST
RxSight, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$4.99
+8.71%Year over year
Reported trailing growth
- Revenue
- -14.3%
- EBITDA
- -61.6%
- EBIT
- -35.1%
- EPS
- -45.5%
- Free cash flow
- +184.0%
- Operating cash flow
- +226.9%
Forward estimates
Based on analyst estimates
- Revenue
- +35.4%
- EBITDA
- +44.5%
- EPS
- +35.3%
Three-year CAGR
- Revenue
- +40.0%
- EBITDA
- -49.7%
- EBIT
- -30.7%
- Net income
- -41.8%
- EPS
- -33.8%
- Free cash flow
- +13.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026